AKERO THERAPEUTICS INC
NASDAQ: AKRO (Akero Therapeutics, Inc.)
Last update: 7 hours ago54.23
-0.11 (-0.20%)
| Previous Close | 54.34 |
| Open | 54.40 |
| Volume | 1,210,391 |
| Avg. Volume (3M) | 2,154,660 |
| Market Cap | 4,464,006,144 |
| Price / Book | 4.67 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Diluted EPS (TTM) | -3.75 |
| Total Debt/Equity (MRQ) | 3.34% |
| Current Ratio (MRQ) | 16.80 |
| Operating Cash Flow (TTM) | -262.63 M |
| Levered Free Cash Flow (TTM) | -177.47 M |
| Return on Assets (TTM) | -18.52% |
| Return on Equity (TTM) | -27.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Akero Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -3.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -1.13 |
|
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.37% |
| % Held by Institutions | 109.31% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 56.00 (Jefferies, 3.26%) | Hold |
| Median | 54.00 (-0.42%) | |
| Low | 54.00 (HC Wainwright & Co., -0.42%) | Hold |
| 54.00 (Canaccord Genuity, -0.42%) | Hold | |
| Average | 54.67 (0.81%) | |
| Total | 3 Hold | |
| Avg. Price @ Call | 54.01 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 10 Oct 2025 | 54.00 (-0.42%) | Hold | 53.88 |
| 04 Sep 2025 | 72.00 (32.77%) | Buy | 44.03 | |
| Canaccord Genuity | 09 Oct 2025 | 54.00 (-0.42%) | Hold | 54.08 |
| Jefferies | 09 Oct 2025 | 56.00 (3.26%) | Hold | 54.08 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 07 Nov 2025 | Announcement | Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025 |
| 09 Oct 2025 | Announcement | Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion |
| 07 Oct 2025 | Announcement | Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025 |
| 28 Aug 2025 | Announcement | Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |